Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03941262
Title Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors NKMax America, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.